|
|
| | 2-Hydroxyoleicacid Basic information |
| | 2-Hydroxyoleicacid Chemical Properties |
| Melting point | 47-50oC | | storage temp. | room temp | | solubility | DMSO: >20mg/mL | | form | Solid | | color | white to tan | | InChI | 1S/C18H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h9-10,17,19H,2-8,11-16H2,1H3,(H,20,21)/b10-9- | | InChIKey | JBSOOFITVPOOSY-KTKRTIGZSA-N | | SMILES | CCCCCCCC\C=C/CCCCCCC(O)C(O)=O |
| Hazard Codes | Xi | | Risk Statements | 41 | | Safety Statements | 26-39 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Dam. 1 |
| | 2-Hydroxyoleicacid Usage And Synthesis |
| Chemical Properties | Off-White to Pale Beige Solid | | Uses | 2OHOA has been used as:
- a modulator of the sphingolipid and glycerophospholipid pathway to study its effects on myelination in mice Charcot–Marie–Tooth type 1A (CMT1A) myelinopathy and myelinating dorsal root ganglia cultures
- in biophysical studies to study its effects on artificial membranes
- to study its interactions with major membrane lipid films
| | Uses | An oleic acid synthetic analog that is an effective non-toxic anticancer drug with a wide spectrum against different types of cancer. An antihypertensive. | | Definition | ChEBI: 2-hydroxyoleic acid is a 2-hydroxy fatty acid that is oleic acid which carries a hydroxy group at position 2. It is an orally bioavailable synthetic hydroxylated fatty acid which modulates the lipid content of cancer cell membranes and induces cell cycle arrest and apoptosis in several cancer cell lines. It has a role as an antineoplastic agent, an apoptosis inducer and an antihypertensive agent. It is a 2-hydroxy fatty acid, a long-chain fatty acid and a hydroxy monounsaturated fatty acid. It is functionally related to an oleic acid. It is a conjugate acid of a 2-hydroxyoleate. | | Biochem/physiol Actions | 2-Hydroxy oleic acid (2OHOA) is a derivative of oleic acid. It plays a role in membrane organization, alterations inmembrane fluidity, an increase of the tendency to form non-lamellar structures, and remodeling of microdomains by interacting with the lipids in membranes of pathological cells. | | in vivo | (Rac)-Idroxioleic acid markedly and significantly inhibits tumour growth in nude mice infected with Jurkat cells[1].
| Animal Model: | 6-week-old nude male mice (Jurkat cells xenograft model)[1] | | Dosage: | 600 mg/kg | | Administration: | Oral administration; daily; for 21 days | | Result: | Markedly and significantly inhibited tumour growth. |
|
| | 2-Hydroxyoleicacid Preparation Products And Raw materials |
|